SPR741, an Antibiotic Adjuvant, Potentiates theIn VitroandIn VivoActivity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii | Zendy

Daniel V. Zurawski | Zendy; Alexandria A. Reinhart | Zendy; Yonas A. Alamneh | Zendy; Michael J. Pucci | Zendy; Yuanzheng Si | Zendy; Rania Abu-Taleb | Zendy; Jonathan P. Shearer | Zendy; Samandra T. Demons | Zendy; Stuart D. Tyner | Zendy; Troy Lister | Zendy

Open Access

SPR741, an Antibiotic Adjuvant, Potentiates theIn VitroandIn VivoActivity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii

Author(s) -

Daniel V. Zurawski,

Alexandria A. Reinhart,

Yonas A. Alamneh,

Michael J. Pucci,

Yuanzheng Si,

Rania Abu-Taleb,

Jonathan P. Shearer,

Samandra T. Demons,

Stuart D. Tyner,

Troy Lister

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01239-17

Subject(s) - acinetobacter baumannii , antibiotics , microbiology and biotechnology , in vivo , pneumonia , drug , drug resistance , adjuvant , medicine , biology , pseudomonas aeruginosa , pharmacology , bacteria , immunology , genetics

Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR) A. baumannii strain. In standard in vitro assays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research